Internship

Intern I – Copywriting

Posted on 2/15/2025

Dexcom

Dexcom

5,001-10,000 employees

Develops continuous glucose monitoring systems

Compensation Overview

$22 - $25/hr

Company Does Not Provide H1B Sponsorship

Remote in USA

Candidates must be based in the United States.

Category
Content & Writing
Copywriting
Required Skills
Communications
Journalism
Marketing
Requirements
  • Be studying for a bachelor’s degree, preferably in English, journalism, creative writing, communications, marketing or public relations
  • Possess previous writing experience or interest
  • Possess good communication and organizational skills and be able to adapt to changes in priorities
Responsibilities
  • Work closely with the creative team, participating in creative briefings, brainstorm sessions, and client meetings
  • Support copy development for marketing collateral, including emails, brochures, website copy, blog posts, paid social content, and more
  • Help us develop strong, sound, and innovative concepts
  • Ensure brand consistency in all copy by following existing writing guidelines
  • Proofread and edit copy for grammar and style

Dexcom develops and sells continuous glucose monitoring (CGM) systems designed to help individuals manage diabetes. The main product, the Dexcom G6 CGM System, provides users with real-time glucose readings, enabling better control of their condition. The system includes a sensor that measures glucose levels and sends the data to a display device or smartphone app. This allows users to monitor their glucose levels throughout the day without the need for fingerstick tests. Dexcom differentiates itself from competitors by offering a user-friendly interface and advanced data analytics through its Dexcom CLARITY software, which helps users and healthcare providers make informed decisions based on glucose trends. The company's goal is to enhance the quality of life for diabetes patients by providing reliable and accessible glucose monitoring solutions.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • The global diabetes management market is projected to reach $98.4 billion by 2028.
  • Dexcom's expansion of GenAI across its portfolio offers growth opportunities.
  • Wearable health tech market is growing at 15.9% CAGR, benefiting Dexcom.

What critics are saying

  • Increased competition from new health tech wearables like MindMics' earbuds.
  • Criticism of the approval process for health tech devices may delay product launches.
  • Privacy concerns may arise from Dexcom's GenAI platform's data handling.

What makes Dexcom unique

  • Dexcom's GenAI platform offers personalized insights for diabetes management.
  • Stelo is the first GenAI-enabled CGM, enhancing user experience with tailored guidance.
  • Dexcom's integration of AI positions it as a leader in CGM technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Galway Beo
Mar 22nd, 2025
Dexcom opening date hiring 1000 jobs as highly skilled workers wanted

Dexcom opening date hiring 1000 jobs as highly skilled workers wanted.

ETF Daily News
Mar 20th, 2025
Independent Advisor Alliance Invests $244,000 in DexCom, Inc. (NASDAQ:DXCM)

Independent Advisor Alliance invests $244,000 in DexCom, Inc. (NASDAQ:DXCM).

Stock Titan
Feb 27th, 2025
Dexcom Announces Upcoming Conference Presentation

Dexcom (NASDAQ:DXCM) has announced its upcoming participation in the 46th Annual Raymond James Institutional Investors Conference.

MarketBeat
Feb 23rd, 2025
Fisher Funds Management LTD Invests $96.51 Million in DexCom, Inc. (NASDAQ:DXCM)

Fisher Funds Management LTD invests $96.51 million in DexCom, Inc. (NASDAQ:DXCM).

ETF Daily News
Jan 17th, 2025
Capital Investment Advisors LLC Invests $206,000 in DexCom, Inc. (NASDAQ:DXCM)

Capital Investment Advisors LLC invests $206,000 in DexCom, Inc. (NASDAQ:DXCM).

INACTIVE